Skip to main
CHE

Chemed (CHE) Stock Forecast & Price Target

Chemed (CHE) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Chemed Corp's positive outlook is supported by strong demand growth in both its VITAS and Roto-Rooter segments. The VITAS segment, being the nation's leading hospice provider, has demonstrated significant long-term growth potential and profitability improvements, even amid competitive pressures and regulatory caps in specific markets like Florida. Additionally, projections indicate that VITAS is set to rebound in 2026, which, combined with an improving economic landscape, suggests favorable conditions for continued revenue acceleration.

Bears say

Chemed Corp faces several financial challenges projected to impact its future earnings and growth. The anticipated macroeconomic headwinds are expected to soften consumer demand for both the Roto-Rooter and VITAS segments, leading to a downward revision of FY2025 to FY2027 earnings per share estimates by 10% and lowering the price target significantly. Additionally, operational difficulties are exemplified by a 520 basis point decline in Roto-Rooter's adjusted EBITDA margin and a year-over-year decrease in lead generation, highlighting concerns over increased costs and reduced demand that could adversely affect overall profitability.

Chemed (CHE) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Chemed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Chemed (CHE) Forecast

Analysts have given Chemed (CHE) a Buy based on their latest research and market trends.

According to 4 analysts, Chemed (CHE) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $555.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $555.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Chemed (CHE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.